| Bioactivity | Spirapril is a potent and cross the blood-brain barrier angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active prodrug of Spiraprilat and can be used for the research of hypertension, congestive heart failure[1][2][3]. |
| In Vivo | Spirapril (feeding needle; 10 mg/kg; 3 weeks) decreases alcohol intake in TGM123 mice and dose not reduce the alcohol consumption in TLM mice[2].Spirapril shows a 40.2% reduction in ACE activity in brain membrane from treated-mice[2].Spirapril can crosses the blood-brain barrier and suppresses the transgene effect in the experiments[2].Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats[3]. |
| Name | Spirapril |
| CAS | 83647-97-6 |
| Formula | C22H30N2O5S2 |
| Molar Mass | 466.61 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Noble S, Sorkin EM. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs. 1995 May;49(5):750-66. [2]. Maul B, et al. Alcohol consumption is controlled by angiotensin II. FASEB J. 2001 Jul;15(9):1640-2. [3]. Olivetti G, et al. Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993 Mar;21(3):362-70. |
Spirapril
CAS: 83647-97-6 F: C22H30N2O5S2 W: 466.61
Spirapril is a potent and cross the blood-brain barrier angiotensin converting enzyme (ACE) inhibitor with antihypertens
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.